Dividends Inside 
Kyntra Bio, Inc.
KYNB
$6.87 (- $0.26 - 3.65%)
Last updated: 2026-06-16 16:49 UTC
Kyntra Bio, Inc. trades under ticker KYNB on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US31572Q8814, CUSIP 31572Q881.
About the Company
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs, with a primary focus on oncology and rare diseases. Headquartered in San Francisco, California, and incorporated in 1993, the company today centers its efforts on targeted therapies for cancer and anemia-related conditions. A key program is FG-3246, a first-in-class antibody-drug conjugate targeting CD46, being evaluated for metastatic castration-resistant prostate cancer, alongside FG-3180, a related PET imaging biomarker designed to visualize CD46-positive tumors and support patient selection. Kyntra Bio also develops roxadustat, an oral small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase, used for the treatment of anemia in chronic kidney disease and investigated in myelodysplastic syndromes. Through internal R&D and collaboration agreements with partners such as Astellas Pharma and AstraZeneca, Kyntra Bio occupies a specialized role in the healthcare sector, aiming to provide differentiated, mechanism-based therapies across global markets.
Price History
Latest News for KYNB
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
Kyntra Bio Inc (KYNB) reports increased revenue and improved cost management, while advancing key clinical trials and maintaining a strong cash position.
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript
Gaia Vasiliver-Shamis: Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. Joining me on today’s call are Thane Wettig, chief executive officer, David DeLucia, chief financial officer, and Carol Gaddum, vice president of product development. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results, and results of operations, risks related to our business, and certain other business matters.
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of ro
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -4.60% and +52.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial resu